AC Immune Announces Pricing of Underwritten Offering of Common Shares
AC Immune Announces Pricing of Underwritten Offering of Common Shares
Lausanne, Switzerland, December 15, 2023 – AC Immune SA (Nasdaq:ACIU) (the “Company” or “AC Immune”), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it has priced an underwritten offering of 14.3 million of its common shares at a price of USD 3.50 per share.
Related news for (ACIU)
- AC Immune and Takeda Sign Exclusive Option and License Agreement Valued up to $2.1B
- AC Immune to Regain Global Rights to Crenezumab and Semorinemab
- AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer’s and Parkinson diseases
- AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer’s Disease